Read by QxMD icon Read

ASCVD risk

Lisa Gallicchio, Carla Calhoun, David Riseberg, Kathy Helzlsouer
The purpose of this study was to compare the cardiovascular health of Black and White breast cancer patients undergoing adjuvant treatment. Baseline data from a cohort study of Black (n = 45) and White (n = 101) breast cancer patients initiating aromatase inhibitor treatment were analyzed. Participants had a cardiovascular health assessment, including carotid intimal medial thickness measurement, donated a blood sample, and completed a questionnaire. Atherosclerotic cardiovascular disease (ASCVD) event risk scores were calculated...
October 25, 2016: Breast Journal
Nasreen Al Sayed, Khalid Al Waili, Fatheya Alawadi, Saeed Al-Ghamdi, Wael Al Mahmeed, Fahad Al-Nouri, Mona Al Rukhaimi, Khalid Al-Rasadi, Zuhier Awan, Mohamed Farghaly, Mohamed Hassanein, Hani Sabbour, Mohammad Zubaid, Philip Barter
BACKGROUND: Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. METHODS: A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma lipids in the Middle East...
September 28, 2016: International Journal of Cardiology
Tonia de Las Heras Gala, Marie Henrike Geisel, Annette Peters, Barbara Thorand, Jens Baumert, Nils Lehmann, Karl-Heinz Jöckel, Susanne Moebus, Raimund Erbel, Christine Meisinger, Amir Abbas Mahabadi, Wolfgang Koenig
BACKGROUND: The 2013 ACC/AHA guidelines introduced an algorithm for risk assessment of atherosclerotic cardiovascular disease (ASCVD) within 10 years. In Germany, risk assessment with the ESC SCORE is limited to cardiovascular mortality. Applicability of the novel ACC/AHA risk score to the German population has not yet been assessed. We therefore sought to recalibrate and evaluate the ACC/AHA risk score in two German cohorts and to compare it to the ESC SCORE. METHODS: We studied 5,238 participants from the KORA surveys S3 (1994-1995) and S4 (1999-2001) and 4,208 subjects from the Heinz Nixdorf Recall (HNR) Study (2000-2003)...
2016: PloS One
Meghan K Edwards, Ovuokerie Addoh, Paul D Loprinzi
OBJECTIVE: The predictive validity of the Pooled Cohort risk (PCR) equations for residual-specific mortality (deaths not resulting from the 9 leading causes of death) among a national sample of U.S. adults has not previously been evaluated, which was the purpose of this study. METHODS: Data from the 1999-2010 National Health and Nutrition Examination Survey were used, with participants followed up through December 31, 2011 to ascertain mortality status. The analyzed sample included 11,171 cardiovascular disease-free adults (40-79 years of age)...
October 4, 2016: Postgraduate Medicine
Ibrahim Al-Zakwani, Abdullah Shehab, Ali T Al-Hinai, Wael Al Mahmeed, Mohamed Arafah, Omer Al Tamimi, Mahmoud Al Awadhi, Faisal Al Anazi, Haitham Amin, Khalid Al Nemer, Shorook Al Herz, Othman Metwally, Akram Alkhadra, Mohammed Fakhry, Hossam Elghetany, Abdel Razak Medani, Afzal Hussein Yusufali, Obaid Al Jassim, Omar Al Hallaq, Fahad Omar, Ahmed S Baslaib, Khalid Al Waili, Khamis Al Hashmi, Vasilios Athyros, Khalid Al Rasadi
BACKGROUND: Few studies assessed gender disparity in lipid goal attainment in the Arabian Gulf. Hence, we estimated gender gaps in lipid target achievements among patients at high and very high atherosclerotic cardiovascular disease (ASCVD) risk in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS). METHODS: The study (conducted between November 22, 2009 and July 7, 2010) included 4,384 patients (≥18 years) on lipid lowering drugs at high and very ASCVD risk status from outpatient clinics of 177 specialists and primary care physicians in 6 Arabian Gulf countries...
October 2, 2016: Current Vascular Pharmacology
Xueli Yang, Jianxin Li, Dongsheng Hu, Jichun Chen, Ying Li, Jianfeng Huang, Xiaoqing Liu, Fangchao Liu, Jie Cao, Chong Shen, Ling Yu, Fanghong Lu, Xianping Wu, Liancheng Zhao, Xigui Wu, Dongfeng Gu
BACKGROUND: -The accurate assessment of individual risk can be of great value to guiding and facilitating prevention of atherosclerotic cardiovascular disease (ASCVD). However, prediction models in common use were primarily formulated in white populations. The project is aimed to develop and validate ten-year risk prediction equations for ASCVD from four contemporary Chinese cohorts. METHODS: -Two prospective studies followed up together with a unified protocol were used as the derivation cohort to develop 10-year ASCVD risk equations in 21 320 Chinese participants...
September 28, 2016: Circulation
Nathan D Wong, Daphnee Young, Yanglu Zhao, Huy Nguyen, Jared Caballes, Irfan Khan, Robert J Sanchez
BACKGROUND: The 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline identifies 4 statin-eligible groups: (1) known atherosclerotic cardiovascular disease (ASCVD) aged ≥21 years, (2) low-density lipoprotein cholesterol (LDL-C) ≥ 190 mg/dL (4.9 mmol/L) aged ≥21 years, (3) diabetes mellitus aged 40 to 75 years with LDL-C 70 to 189 mg/dL (1.8-4.9 mmol/L), or (4) ≥7.5% 10-year ASCVD risk aged 40 to 75 years with LDL-C 70 to 189 mg/dL (1...
September 2016: Journal of Clinical Lipidology
Kelly Shum, Amber Solivan, Parham Parto, Nichole Polin, Eiman Jahangir
BACKGROUND: Because of the improvements in survival rates, patients with breast cancer are now more likely to die from cardiovascular disease than from cancer. Thus, providing appropriate preventive cardiovascular care to patients with cancer is of the utmost importance. METHODS: We retrospectively compared the cardiovascular risk and management of 146 women treated at the Cardio-Oncology (Cardio-Onc) and the Obstetrics and Gynecology (Ob-Gyn) clinics. We calculated cardiovascular risk using the American College of Cardiology (ACC)/American Heart Association (AHA) atherosclerotic cardiovascular disease (ASCVD) risk calculator and the Framingham Risk Score Calculator...
2016: Ochsner Journal
Hussain Isma'eel, David Min, Laila Al-Shaar, Rory Hachamovitch, Sandra Halliburton, James Gentry, Brian Griffin, Paul Schoenhagen, Dermot Phelan
The 2013 American College of Cardiology/American Heart Association cardiovascular prevention guidelines use a new pooled cohort equation (PCE) to predict 10-year risk of atherosclerotic cardiovascular disease (ASCVD) events which form the basis of treatment recommendations. Coronary artery calcium score (CACS) has been proposed as a means to assess atherosclerotic risk. We sought to study the level of agreement in predicted ASCVD risk by CACS and PCE-calculated models and the potential impact on therapy of additional CACS testing...
August 23, 2016: American Journal of Cardiology
Michael J Blaha
Current American College of Cardiology/American Heart Association guidelines for the management of patients with elevated blood cholesterol increasingly emphasize assessment of atherosclerotic cardiovascular disease (ASCVD) risk in deciding when to initiate pharmacotherapy. The decision to treat is based primarily on mathematical integration of traditional risk factors, including age, sex, race, lipid values, systolic blood pressure, hypertension therapy, diabetes mellitus, and smoking. Advanced risk testing is selectively endorsed for patients when the decision to treat is otherwise uncertain, or more broadly interpreted as those patients who are at so-called "intermediate risk" of ASCVD events using traditional risk factors alone...
September 15, 2016: American Journal of Cardiology
Meghan K Edwards, Elizabeth Crush, Paul D Loprinzi
PURPOSE: The pooled cohort equations were developed in 2013 by the American College of Cardiology/American Heart Association Task Force to predict an individual's 10-year risk of an atherosclerotic cardiovascular disease (ASCVD) event. The purpose of the present study was to evaluate how predicted 10-year ASCVD event risk varies as a function of daily dietary behavior. DESIGN: Cross-sectional. SETTING: National Health and Nutrition Examination Survey 2003 to 2006...
September 7, 2016: American Journal of Health Promotion: AJHP
Brittany A Todd, Donald G Lamprecht, Sheila L Stadler
PURPOSE: Prescribing practices within a clinical pharmacy cardiac risk service (CPCRS) and their impact on treatment outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) are described. SUMMARY: National healthcare reforms have increased the population of insured patients and placed increased demands on physicians and other providers. Pharmacists are well trained and positioned to aid in patient care by providing expertise in medication management and patient safety that can result in pharmacotherapy optimization and cost savings...
September 15, 2016: American Journal of Health-system Pharmacy: AJHP
Byung Sub Moon, Jongho Kim, Ji Hyun Kim, Young Youl Hyun, Se Eun Park, Hyung Geun Oh, Cheol Young Park, Won Young Lee, Ki Won Oh, Kyu Beck Lee, Hyang Kim, Sung Woo Park, Eun Jung Rhee
BACKGROUND: The purpose of this study was to investigate the relationship between statin eligibility and the degree of renal dysfunction using the Adult Treatment Panel (ATP) III and the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines in Korean adults. METHODS: Renal function was assessed in 18,746 participants of the Kangbuk Samsung Health Study from January 2011 to December 2012. Subjects were divided into three groups according to estimated glomerular filtration rate (eGFR): stage 1, eGFR ≥90 mL/min/1...
September 2016: Endocrinology and Metabolism
Roberta Florido, Di Zhao, Chiadi E Ndumele, Pamela L Lutsey, John W McEvoy, B Gwen Windham, James S Pankow, Eliseo Guallar, Erin D Michos
BACKGROUND: The effects of some atherosclerotic cardiovascular disease (ASCVD) risk factors vary according to whether an individual has a family history (FHx) of premature coronary heart disease (CHD). Physical activity (PA) is associated with reduced risk of ASCVD, but whether this association varies by FHx status is not well established. METHODS AND RESULTS: We evaluated 9996 participants free of ASCVD at baseline. FHx of premature CHD was defined as CHD occurring in a father before age 55 or mother before age 60...
August 30, 2016: Journal of the American Heart Association
Steven D Barger, Matthew R Cribbet, Matthew F Muldoon
BACKGROUND: Participant-reported health status is a key indicator of cardiovascular health, but its predictive value relative to traditional and nontraditional risk factors is unknown. We evaluated whether participant-reported health status, as indexed by self-rated health, predicted cardiovascular disease, and all-cause mortality risk excess of 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores and 5 nontraditional risk biomarkers. METHODS AND RESULTS: Analyses used prospective observational data from the 1999-2002 National Health and Nutrition Examination Surveys among those aged 40 to 79 years (N=4677)...
2016: Journal of the American Heart Association
Eugene Han, Gyuri Kim, Namki Hong, Yong-Ho Lee, Dong Woo Kim, Hyun Joon Shin, Byung-Wan Lee, Eun Seok Kang, In-Kyu Lee, Bong-Soo Cha
BACKGROUND: Acid-base imbalance has been reported to increase incidence of hypertension and diabetes. However, the association between diet-induced acid load and cardiovascular disease (CVD) risk in the general population has not been fully investigated. METHODS: This was a population-based, retrospectively registered cross-sectional study using nationally representative samples of 11,601 subjects from the Korea National Health and Nutrition Examination Survey 2008-2011...
2016: Cardiovascular Diabetology
Emma Kaplan-Lewis, Judith A Aberg, Mikyung Lee
In the current era of available therapy for human immunodeficiency virus (HIV), life expectancy for persons living with HIV (PLWH) nears that of the general population. Atherosclerotic cardiovascular disease (ASCVD) has become a particular burden for PLWH and society at large. PLWH have historically been shown to have an excess of cardiovascular risk and subsequent events when compared to the general population. Potential explanations include the increased prevalence of traditional risk factors, direct inflammatory and immunological effects from the HIV virus itself, and metabolic adverse effects of anti-retroviral therapy (ART)...
October 2016: Current HIV/AIDS Reports
Martin Bødtker Mortensen, Valentin Fuster, Pieter Muntendam, Roxana Mehran, Usman Baber, Samantha Sartori, Erling Falk
BACKGROUND: The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend primary prevention with statins for individuals with ≥7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD). Everyone living long enough will become eligible for risk-based statin therapy due to age alone. OBJECTIVES: This study sought to personalize ACC/AHA risk-based statin eligibility using noninvasive assessment of subclinical atherosclerosis...
August 30, 2016: Journal of the American College of Cardiology
Giulia Bruzzone, Giorgia Corbelli, Paola Belci, Annalaura Cremonini, Aldo Pende, Livia Pisciotta
BACKGROUND: Atherosclerotic Cardiovascular Disease (ASCVD) is the first cause of death in Western Countries. Several risk factors contribute to generate atherosclerosis and the preventive therapeutic approaches, in particular statin therapy, reduce the mortality. However, the residual risk in statin treated patients remains significant, despite reaching the low density lipoproteins cholesterol (LDL-C) goals. METHODS: we reviewed the literature published in PUB-MED to discuss the role of residual dyslipidemia in particular high density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and lipoprotein(a) [Lp(a)], genetic factors, suboptimal implementation of lifestyle therapy, mood disorders associated to low compliance to application of evidence-based therapies or related to ASCVD...
August 22, 2016: Current Pharmaceutical Design
Y Li, S P Zhao, P Ye, X W Yan, Y M Mu, Y D Wei, D Y Hu
OBJECTIVE: To analyze the current status of cholesterol goal attainment for the primary and secondary prevention of cardiovascular disease in dyslipidemia patients using data from the DYSIS-China study. METHODS: Based on criteria defined in the 2014 China Cholesterol Education Program (CCEP) and the 2007 Chinese guidelines for the prevention and treatment of dyslipidemia in adults, 25 317 dyslipidemia patients enrolled in the DYSIS-China study (from March 2012 to October 2012) were stratified to the atherosclerotic cardiovascular disease(ASCVD) primary prevention and secondary prevention groups...
August 24, 2016: Zhonghua Xin Xue Guan Bing za Zhi
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"